Liquid Plasma vs Thawed Plasma: Tracking Coagulation Factor Activity Changes During Storage

This study demonstrates that Liquid Plasma, despite showing reduced levels of Factors V, VII, and VIII and Protein S compared to Thawed Plasma by its expiration date, maintains adequate fibrinogen and Protein C activity, supporting its viability as an alternative for emergency and massive transfusions.

The Gist

Imagine you are running a busy emergency kitchen. When a customer (a trauma patient) comes in bleeding, you need to serve them a "plasma soup" immediately to stop the bleeding.

For years, your kitchen had a strict rule: you could only serve soup that had been frozen and then thawed right before serving. This "Thawed Plasma" (TP) is like a fresh meal, but it has a catch: once you take it out of the freezer, it only stays good for 5 days. After that, it has to be thrown away. This creates a nightmare for your inventory: you either have too much soup that goes bad (waste), or you run out just when you need it most, forcing you to frantically thaw more while the patient waits.

Enter the new contender: Liquid Plasma (LQP). Think of this as a "ready-to-serve" soup that never needed to be frozen in the first place. It sits in the fridge and stays good for 26 days. It's a game-changer for inventory management because you can keep a big, reliable stock without the fear of it expiring in a few days.

But here's the big question: Is this "ready-to-serve" soup just as nutritious and effective as the "freshly thawed" soup? Does it have all the right ingredients to stop the bleeding?

This study is like a nutritional lab test where scientists compared the two soups to see if the Liquid Plasma loses its "power" over time.

The Ingredients (Coagulation Factors)

Plasma isn't just water; it's packed with special "repair tools" (coagulation factors) that help blood clot. The scientists tested the most important ones:

• Fibrinogen: The main "glue" that holds the clot together.
• Protein C & S: The "traffic cops" that regulate the clotting so it doesn't go crazy.
• Factors V, VII, and VIII: The "specialized workers" that speed up the repair process.

The Findings: What Happened During Storage?

1. The "Glue" and "Traffic Cops" Stayed Strong
The most important finding is that the Fibrinogen (the glue) and Protein C (a key regulator) in the Liquid Plasma remained just as strong on Day 26 (the very last day it's allowed to be used) as they were in the Thawed Plasma on Day 5.

• Analogy: Imagine the Liquid Plasma is a battery. Even after sitting on the shelf for 26 days, the "glue" battery is still fully charged, just like the fresh Thawed Plasma battery.

2. The "Specialized Workers" Lost Some Energy
However, some of the specialized workers did lose a bit of power over time.

• Factor V and Protein S: These dropped significantly in the Liquid Plasma. By Day 26, they were only about 50% as active as they were in the fresh Thawed Plasma.
• Factor VIII: This one dropped a little bit, but not as much as the others.
• Factor VII: This one was interesting. It started high but slowly drained over the 26 days, ending up slightly lower than the fresh Thawed Plasma, but still at a level considered "good enough" for emergency work.

3. The "Day 27" Surprise
The scientists even tested the Liquid Plasma one day after it expired (Day 27). They found that the ingredients didn't suddenly rot or disappear overnight. The levels were stable, suggesting that the "expiration date" might actually be a bit conservative.

The Verdict: Is Liquid Plasma Good Enough?

Yes, for emergencies.

Think of it like this: If you are in a car crash and bleeding out, you don't need a gourmet meal with every single vitamin perfectly preserved. You need enough glue and enough speed to stop the bleeding right now.

• The Good News: The Liquid Plasma has plenty of "glue" (Fibrinogen) and enough "speed" (Factor VII) to do the job. It is a viable, life-saving alternative for emergency rooms and massive trauma situations.
• The Trade-off: It has less of some specific "specialized workers" (Factors V and S). This means it might not be the perfect choice for every single medical situation (like non-emergency surgery), but for the "stop the bleeding now" scenarios, it works just as well as the fresh Thawed Plasma.

Why Does This Matter?

By switching to Liquid Plasma, hospitals can:

1. Stop the Waste: They won't have to throw away thousands of dollars of plasma every year because it expired after 5 days.
2. Save Time: No more waiting for frozen bags to thaw. The plasma is ready instantly.
3. Save Lives: Faster access to plasma means faster treatment for trauma patients.

In short: Liquid Plasma is like a "ready-to-eat" meal that stays fresh for a month. While it loses a few specific vitamins over time, it still has all the essential nutrients needed to save a life in an emergency, making it a fantastic tool for modern medicine.

Technical Summary

1. Problem Statement

In acute trauma and massive transfusion protocols, the rapid availability of plasma is critical. Standard practice involves using Thawed Plasma (TP), which is Frozen Plasma (FFP) thawed and stored at 1–6°C for up to 5 days (Day 5). However, TP has a short shelf life, leading to significant inventory wastage and potential delays if all thawed units are exhausted and frozen units require thawing.

Liquid Plasma (LQP) is a never-frozen alternative stored at 2–6°C with a 26-day shelf life, offering superior inventory flexibility and reduced wastage. Despite its clinical adoption, there is limited data characterizing the hemostatic profile of LQP over its entire storage duration. Specifically, it is unclear how the activity levels of key coagulation factors (particularly labile ones like Factor V, VII, and VIII) change during the 26-day storage period and how they compare to the standard Day 5 Thawed Plasma.

2. Methodology

The study employed a rigorous experimental design using Bayesian statistical modeling to track coagulation factor dynamics.

• Sample Collection:
  • Liquid Plasma (LQP): 26 units (Blood Group A) obtained from the American Red Cross. Samples were collected at Day 15 (mid-expiration), Day 26 (expiration), and Day 27 (1 day post-expiration).
  • Thawed Plasma (TP): 31 units (Groups A, O, AB) derived from FFP, thawed, and stored for Day 5.
  • Processing: LQP units were irradiated to prevent Transfusion-Associated Graft-versus-Host Disease (TA-GVHD). Samples were aliquoted, frozen at -70°C, and thawed at 37°C prior to testing.
• Measurements:
  • Coagulation factors measured: Fibrinogen, Protein C (PC), Protein S (PS), Factor V (FV), Factor VII (FVII), and Factor VIII (FVIII).
  • Analyzers: ACL TOP 750 (for factors) and Siemens CS-5100 (for fibrinogen).
• Statistical Approach:
  • Bayesian Statistics: Used to estimate posterior distributions for mean activities and differences between groups.
  • Multilevel Piecewise Linear Regression: Modeled the rate of change in factor activity per day across two distinct periods: Day 15–26 and Day 26–27. This allowed for the quantification of degradation rates while accounting for longitudinal data from individual units.
  • Comparisons: LQP26 vs. TP5; ABO group comparisons; Segment vs. Bag correlation.

3. Key Contributions

• Longitudinal Stability Analysis: Unlike previous studies that may have only compared fresh vs. expired products, this study tracks factor activity at three specific time points (Day 15, 26, 27) to map the degradation trajectory of LQP.
• Quantification of Degradation Rates: The study provides specific daily degradation rates for coagulation factors using piecewise linear regression, distinguishing between stable factors and those that degrade significantly over time.
• Validation of LQP for Emergency Use: By comparing LQP at the very end of its shelf life (Day 26) against standard TP (Day 5), the study provides evidence-based support for using LQP in massive transfusion protocols without compromising critical hemostatic factors.
• Segment vs. Bag Correlation: The study identified a discrepancy in Factor V measurements between blood bag segments and the main unit, highlighting a methodological limitation in longitudinal sampling for labile factors.

4. Key Results

A. Comparison: LQP (Day 26) vs. TP (Day 5)

• Comparable Factors:
  • Fibrinogen: LQP26 (257 mg/dL) vs. TP5 (246 mg/dL). No significant difference.
  • Protein C: LQP26 (100.4%) vs. TP5 (108.7%). No significant difference.
  • Factor VII: LQP26 (55.0%) vs. TP5 (59.7%). While slightly lower, the credible intervals overlapped, suggesting comparability.
• Significantly Lower in LQP:
  • Protein S: LQP26 (28.0%) was less than half of TP5 (66.4%).
  • Factor V: LQP26 (42.6%) was significantly lower than TP5 (72.0%).
  • Factor VIII: LQP26 (48.8%) was lower than TP5 (59.2%), though the magnitude of difference was smaller than FV or PS.

B. Stability During Storage (Day 15 to Day 26)

• Factor VII: Showed a significant decline, decreasing at a rate of -3.49% per day.
• Stable Factors: Fibrinogen, Protein C, Protein S, Factor V, and Factor VIII remained relatively stable during this period, with daily change rates close to zero or negligible.
• Post-Expiration (Day 26 to 27): No significant changes were observed in any factor between Day 26 and Day 27, suggesting stability even one day past the labeled expiration.

C. ABO Group Influence

• Analysis of TP units showed no significant differences in coagulation factors between Group A/AB and Group O, validating the direct comparison between the Group A LQP units and the mixed-group TP units.

5. Significance and Clinical Implications

• Viability for Emergency Resuscitation: The study concludes that LQP is a viable alternative to TP for emergent transfusions and massive transfusion protocols. The critical factors for acute hemostasis—specifically Fibrinogen and Factor VII—remain at adequate levels in LQP even at the end of its 26-day shelf life.
• Inventory Management: The extended shelf life of LQP (26 days vs. 5 days for TP) allows blood banks to maintain a larger, more flexible inventory, significantly reducing product wastage (the authors noted a system-wide reduction from 17% to 13%).
• Limitations in Non-Emergent Settings: Due to the substantial loss of Protein S and Factor V, LQP is not a suitable substitute for Fresh Frozen Plasma (FFP) in non-emergent settings where specific factor replacement is required.
• Regulatory Context: While LQP and TP did not meet the strict European Directorate for the Quality of Medicines (EDQM) average requirement for FVIII (70 IU/100mL) found in fresh FFP, they met the lower threshold for pathogen-reduced plasma (50 IU/100mL), supporting their use in acute care.

Conclusion: Liquid Plasma retains sufficient activity of the most critical coagulation factors (Fibrinogen, PC, FVII) to support acute trauma resuscitation, offering a superior logistical alternative to Thawed Plasma despite lower levels of Factor V and Protein S.